PMEPro Medicus

Pro Medicus shares surged strongly alongside a broad ASX healthcare sector rally of over 7.7%, likely driven by sector-wide capital flows into health stocks.

Pro Medicus shares surged after announcing multiple new US contract wins, including a 7-year A$16 million deal with TidalHealth.

Pro Medicus surged following contract wins and broker confidence, as highlighted by a 8.34% rally on April 16, 2026.

Pro Medicus announced long-term US contract renewals worth A$40m, reinforcing its US partnerships and driving the stock up.

Broad sector rotation into beaten-down growth stocks after a previous tech-led sell-off, with articles on the pullback as a hidden opportunity for long-term investors.

PME fell 9% as part of a broad tech sector sell-off driven by Middle East escalation fears, with the entire ASX 200 slumping and other tech names also declining.

PME shares rose 9.78% on February 25, 2026, likely driven by a combination of positive analyst commentary and market sentiment, with no single definitive company-specific catalyst identified.

Pro Medicus surged after being highlighted as a top ASX 200 stock to hold until 2036 and amid a broader sector rotation away from tech.

PME shares fell 6-9% as part of a broad tech sector sell-off, with gold and silver stocks outperforming

Pro Medicus shares fell sharply amid a broad tech selloff on the ASX, driven by Trump tariff concerns.

PME shares continued a strong rebound after a prior sell-off, aided by bullish broker commentary and broad technology sector support.

PME shares bounced 7.7% on February 16th, likely as part of a broader market recovery following the recent AI selloff, with the move highlighted in the daily market wrap.

Pro Medicus shares plunged after its H1 FY26 results, despite strong earnings, likely due to valuation concerns and profit-taking.

Pro Medicus shares plunged despite a strong H1 FY26 earnings result, as investors sold off on the news in a broader ASX tech sell-off.